Johnson & Johnson MedTech, the global leader in heart recovery, will feature the latest evidence demonstrating the survival benefit of Impella® heart pump technology at the American College of ...

The first clinical guidance for cardiogenic shock will be presented at the American College of Cardiology Scientific Session ...

ATLANTA -- Routine use of the Impella CP microaxial flow pump significantly improved survival in patients with infarct-related cardiogenic shock, the randomized DanGer Shock trial showed.

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

Recently, however, the DanGer Shock trial delivered a decisively positive result for Impella in highly selected patients with STEMI complicated by cardiogenic shock. On the strength of that trial, the ...

Patients with severe heart failure or cardiogenic shock often require assistance from MCS devices such as venoarterial ...

As Healio previously reported, routine use of a microaxial flow pump (Impella CP ... care alone for patients with STEMI and cardiogenic shock. The class IIA guideline recommendation is specific ...